Drug intelligence / Profile preview

Dual anti-B830-ADC

Development stage: Preclinical
Lead developer: Nanolattix
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Dual anti-B830-ADC is a bispecific antibody-drug conjugate (ADC) being developed by Nanolattix for the treatment of solid tumors. The drug candidate targets the B830 antigen and is currently in the preclinical stage of development. It is specifically being evaluated for its potential in treating lung cancer, pancreatic cancer, and esophageal cancer. By utilizing a bispecific antibody scaffold, the conjugate aims to enhance tumor-specific binding and the subsequent internalization of its cytotoxic payload to improve therapeutic efficacy and reduce off-target toxicity.

Other names: Dual anti-B830

Beyond the preview

Go deeper on Dual anti-B830-ADC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dual anti-B830-ADC.

Explore the full profile